THRIVE Drug Patent Profile
✉ Email this page to a colleague
When do Thrive patents expire, and when can generic versions of Thrive launch?
Thrive is a drug marketed by Glaxosmithkline Cons and is included in two NDAs.
The generic ingredient in THRIVE is nicotine polacrilex. There are thirty drug master file entries for this compound. Fifty-eight suppliers are listed for this compound. Additional details are available on the nicotine polacrilex profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Thrive
A generic version of THRIVE was approved as nicotine polacrilex by P AND L on March 15th, 1999.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for THRIVE?
- What are the global sales for THRIVE?
- What is Average Wholesale Price for THRIVE?
Summary for THRIVE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Clinical Trials: | 56 |
| DailyMed Link: | THRIVE at DailyMed |
Recent Clinical Trials for THRIVE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Florida | PHASE1 |
| Assistance Publique - Hôpitaux de Paris | PHASE2 |
| Chang Gung Memorial Hospital | NA |
US Patents and Regulatory Information for THRIVE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline Cons | THRIVE | nicotine polacrilex | GUM, CHEWING;BUCCAL | 077658-001 | Jun 19, 2007 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Glaxosmithkline Cons | THRIVE | nicotine polacrilex | GUM, CHEWING;BUCCAL | 077656-001 | Jun 19, 2007 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
